Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011, for Biozone Pharmaceuticals, Inc. (formerly International Surf Resorts, Inc.). The company is a Nevada corporation classified as a development-stage entity. During the quarter, the company underwent a significant strategic pivot: on February 22, 2011, prior officers resigned, and new leadership was appointed to pursue medical and pharmaceutical opportunities. On March 1, 2011, the company changed its name to Biozone Pharmaceuticals, Inc. Subsequent to the reporting period (May 16, 2011), the company acquired substantially all assets of Aero Pharmaceuticals, Inc., a manufacturer of dermatological products.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Net Revenue | $0 | $0 |
| Total Operating Expenses | $2,522 | $3,634 |
| Net Loss | $(4,371) | $(3,363) |
| Cash and Cash Equivalents (End of Period) | $2,122,414 | $36,486 |
| Working Capital | $(211,877) | Filing text does not provide a clear value |
| Convertible Notes Payable | $2,250,000 | $0 |
| Net Cash Provided by Financing Activities | $2,099,636 | $0 |
Material Changes Versus Prior Period
- Liquidity Surge: Cash balances increased from $22,778 at December 31, 2010, to $2,122,414 at March 31, 2011. This was driven primarily by the issuance of $2,250,000 in 10% secured convertible bridge notes on March 29, 2011.
- Debt Structure: The company moved from having no debt to carrying $2,250,000 in convertible notes payable, along with $1,849 in accrued interest.
- Operating Expenses: Total operating expenses decreased to $2,522 from $3,634 in the prior year quarter, reflecting a reduction in operational activity during the transition period.
- Net Loss: Net loss increased slightly to $4,371 from $3,363, primarily due to general and administrative costs associated with refocusing the business.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash resources, combined with expected funds from the Baker Cummins operations (acquired post-period), will sustain operations through at least March 31, 2012. However, additional capital will be required for long-term execution.
- Bridge Note Terms: The $2,250,000 in bridge notes mature on September 29, 2011, or upon the closing of a "Target Transaction Financing." If not prepaid or converted by the maturity date, the company faces a penalty fee and an obligation to repay 150% of the principal if the target transaction has not closed.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2011, due to a lack of segregation of duties regarding cash disbursements caused by limited accounting staff.
- Risks: The company has no assurance it will raise additional capital. Failure to do so may require curtailing business development or suspending the business plan. The company is also subject to risks associated with its status as a development-stage entity with no revenue history.
Investor Verification Checklist
- Verify the status and terms of the $2,250,000 convertible bridge notes, specifically the maturity date (September 29, 2011) and the 150% repayment penalty clause if the target transaction fails to close.
- Confirm the details of the subsequent acquisition of Aero Pharmaceuticals (May 16, 2011), including the issuance of 7,724,000 shares and the potential for up to 7,500,000 additional shares based on asset transfers and costs.
- Assess the impact of the ineffective internal controls on financial reporting reliability, given the lack of segregation of duties.
- Monitor the company's ability to secure the "Target Transaction Financing" required to convert or repay the bridge notes without triggering penalties.
- Review the working capital deficit of $(211,877) despite high cash balances, driven by the current liability of the convertible notes.